regenerative-medicine-certification-training

 

 

 

 

 

 

 

The International Association for Stem Cell Application (ISSCA) will be conducting a regenerative medicine certification course for physicians in Buenos Aires Nov. 26-27, 2017. The two-day intensive training course teaches trainees extraction, isolation, and application of PRP, adipose, and bone marrow stem cells.

 

regenerative medicine certification training

MIAMI, Nov. 9, 2017— The International Society for Stem Cell Application (ISSCA), a global leader in regenerative medicine training, has announced plans to conduct regenerative medicine certification training for physicians in Buenos Aires, Argentina November 26 – 27, 2017.

The ISSCA training course, available to qualified physicians interested in adding regenerative medicine to their practice procedures, provides hands-on, practical instruction under the guidance of trained medical experts in a highly visual, interactive, and clinical learning environment.

.ISSCA’s medical professionals teach reintegration and procedural techniques on live patients using different protocols for isolating stem cells. Trainees will participate in different medical cases under the supervision of trained specialists.

This hands-on stem cell training course provides each participant with a live demonstration of the extraction, isolation, and application of PRP, adipose, and bone marrow stem cells. Techniques and materials used in the course, along with high-resolution, step-by-step procedure videos are provided for the participating physician’s future use and reference.

Led by ISSCA’s established team of skilled practitioners, this course is designed specifically to provide personalized instruction. Seats for each course are limited to 8-10 trainees, not only to suit each participant’s individual training needs but also to allow for professional networking.

Participants who complete the training will receive certification that documents their participation in and completion of the training, their and their knowledge and skills in the field of regenerative medicine. Certification candidates are required to provide proof of prior medical training and experience, and successfully complete a written as well as an oral/practical exam. Certification confirms a physician’s expertise in regenerative medicine.

​Certification procedures and requirements are key to the integrity of regenerative medicine. They furnish a reputable credential that is essential not only for patients to see, but also to a physician’s practice.

The Buenos Aires certification training course will mark the 11th event ISSCA has sponsored and hosted thus far in 2017. The organization is working to position itself as a reference point for regenerative medical practitioners worldwide. With a presence in more than 25 countries, physicians interested in certification can check for an ISSCA training course near them by visiting the https://www.stemcelltraining.net/ website, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

.                                                                                                               ###
Regenerative medicine certification training

Stem Cell training Lima Peru

The International Association for Stem Cell Application (ISSCA) has announced plans to host three regenerative medicine symposiums in Istanbul, Turkey, Buenos Aires, Argentina, and Seoul, Korea in 2018. The Seoul symposium will be part of, the 6th Annual International Conference of ISSCA, “Progress and Perspectives,” which will be held in Seoul in November 2018.

 

regenerative-medicine-symposiums-2018 ISSCA

MIAMI, Nov. 9, 2017—The International Association for Stem Cell Application (ISSCA) has announced plans to host three regenerative medicine symposiums in the upcoming year:

  • Istanbul, Turkey, April 2018
  • Buenos Aires, Argentina, August 2018
  • Seoul, Korea, November 2018

The symposium series will culminate in the 6th Annual International Conference of ISSCA, Progress and Perspectives, in Seoul, Korea in November 2018.

The three international symposiums are part of ISSCA’s mission to support a paradigm shift in healthcare from traditional to regenerative medicine in the 21st Century and provide cutting-edge information on developments in all areas of stem cell research. Each event will host a group of renowned international speakers in the field of stem cell and regenerative medicine, who will offer a day of rigorous scientific discourse aimed at physicians.

Each ISSCA symposium will incorporate the biology, medicine, applications, regulations, product development, and commercialization of stem cells. Business opportunities, challenges, and potential strategies for overcoming these challenges will also be addressed.

The central theme of each international symposium is as follows:

•  Istanbul: Advances in Cell Therapies
•  Buenos Aires:  Next Generation Medicine: Adult Stem Cells
•  Seoul: This seminar will be part of the 6th Annual International Conference of ISSCA, “Progress and Perspectives”

Symposium dates and details will be available shortly. To learn more about the ISSCA symposiums and 6th Annual International Conference of ISSCA, visit the stemcellconference.org website, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

.###

Regenerative medicine symposiums 2018 ISSCA

stem cell medicine

Stem cell medicine is based on the concept that physicians can harness the body’s own reserves to heal itself, rather than relying exclusively on drugs or invasive surgical procedures. Stem cell medicine works by deals engineering human stem cells to replace or restore damaged or diseased organs or tissue, or establish normal function in them. While regenerative medicine primarily includes therapies a that utilize stem cells, the term is also used to describe therapies that use progenitor cells, used for many decades in the form of bone marrow transplants, as well as other cellular products such as platelet-rich plasma (PRP).

While both PRP and progenitor cells are widely used in clinical settings, stem cell therapies are still playing catch-up. PRP is used to treat orthopedic injuries and degenerative joint disease.

However, stem cells are in high demand worldwide. The burgeoning field of stem cell medicine is widely understood in a vague sort of way, but few people are aware that there are different kinds of stem cells. They can be derived from different tissue sources, harvested from the patient’s own body or donated. To help establish a better understanding of the stem cell landscape, we’ll start with some basic concepts.

Autologous vs. Allogenic Stem CellsProgenekine

Stem cell treatments are generally divided into two classes:

  • Autologous stem cells – collected from your own body, exclusively for your own use
  • allogeneic stem cells, harvested from another person (donor)

Current clinical trials involving both autologous and allogeneic therapies are taking place all over the world. These trials target a wide range of diseases and conditions, from heart disease to orthopedic conditions, to wound healing.

Autologous treatments using your own stem cells can be performed in the same operative session, which eliminates concerns over your body rejecting donor cells.  Your stem cells are extracted from your tissue, and reinjected back into your body targeting the area or organ that needs mending. This is a one-to-one therapy.

Allogeneic therapies use stem cells donated from another person. Before these cells can be put into a different human body than the one they came from, they must undergo extensive testing for diseases, and the cells are usually culture expanded in laboratories to achieve higher cell counts. Allogeneic therapies are performed under strict FDA guidelines, as these stem cells can eventually scale up in mass production, be stored and potentially distributed to millions of patients.

Stem Cell Types

stem cell medicineAdult stem cells (non-embryonic) are undifferentiated cells found throughout the body that multiply by cell division to replenish dying cells and regenerate damaged tissues.

Stem cells are acquired from various tissue sources, and each tissue source has different potentials for the cells to differentiate. The following information explains these tissue sources and corresponding type of stem cells:

Adult Stem Cells (ASC’s)
In recent decades researchers discovered that stem cells can be found in all adult tissues. These are called adult stem cells, and although they cannot differentiate into every type of cell like embryonic stem cells, they can differentiate into bone, cartilage and adipose (fat) tissue readily. The two most familiar sources of adult stem cells are bone marrow and adipose tissue. More than 2,000 clinical trials have been conducted worldwide using the various tissue sources of adult stem cells.

IPS Cells (induced pluripotent cells)
IPS cells come from adult cells. Their genetic code is biologically manipulated to become pluripotent, which means they can differentiate, or become any other type of cell. Because the genetic code of IPS cells has been altered, they carry a higher risk profile than both adult stem cells and embryonic stem cells.

Embryonic Stem Cells (ES)
Embryonic stem cells, first isolated in mouse embryos in 1981, are derived from the embryo of a human fetus. Controversy has pursued embryonic stem cell research since its inception, over of ethical and religious perceptions. Embryonic stem cells are currently used mainly for research and understanding how regenerative cells work.

Types of Adult Stem Cells

Adult stem cells can be isolated from bone marrow, adipose tissue, umbilical cord blood, peripheral blood, dental pump, and stem cell medicineother sources. Most recently, a large number of clinical trials are focusing on stem cells derived from bone marrow and adipose tissue.

Bone Marrow Stem Cells
Bone marrow stem cells were the first recognized form of adult stem cells in the body. Researchers found they could be used to help heal bone and to replace different cell types in the blood. They could also be used in cancer patients whose bone marrow was destroyed by radiation therapy or chemotherapy. Use of bone marrow stem cells is FDA approved under certain conditions.

The drawback with bone marrow stem cells is that they are difficult to extract and not abundant. In order to be used as a treatment, bone marrow stem cells must be expanded in culture in a lab. The FDA places this therapy in the category of a drug, and requires rigorous oversight and testing.

Adipose Derived Stem Cells
In 2001, researchers and plastic surgeons from the University of Pittsburgh discovered that human fat tissue is a very rich source of mesenchymal stem cells (MSCs),  multipotent stromal cells that can differentiate into a variety of cell types, and the findings were published in Tissue Engineering Journal. Upon publication, this discovery stirred quite an epiphany in the medical and scientific community—until then, adult MSCs were predominantly believed to be strictly a bone marrow product.

###

 

Joseph Purita, M.D.

Buenos Aires Stem Cell Symposium

Joseph Purita, M.D.
Global Stem Cells Group Advisory Board member

Joseph Purita, M.D., is a world-renowned orthopedic surgeon and stem cell pioneer, using cutting edge technology in regenerative medicine in conjunction with stem cell platelet rich plasma (PRP) therapy to treat orthopedic injuries and relieve pain. He is also a pioneer in the use of the laser in orthopedic surgery.

Named a U.S. News and World Report Top Doctor in 2012, Dr. Purita, a renown orthopedic and arthroscopic surgeon, heads Global Stem Cells Group’s Scientific Advisory Board. A pioneer in the use of stem cell and PRP therapy for orthopedic conditions, Dr. Purita has practiced with the Boca Raton Orthopaedic Group in Boca Raton, Florida since 1981. In 2012, Purita gained international attention when he treated New York Yankees pitcher Bartolo Colon’s ligament damage with stem cells, restoring the athlete’s injured shoulder and career. Purita has since treated an array of professional athletes with career-threatening injuries.

Dr. Purita is the director of the Institute of Regenerative and Molecular Orthopedics in Boca Raton, Florida, specializing in the use of stem cells and PRP injections for use in sports medicine and other musculoskeletal conditions. The Institute has treated some of the most prominent professional athletes from all major sports in both the U.S.. and abroad.

He is an instructor and proctor of surgeons in the use of lasers in arthroscopic and orthopedic surgery at a variety of area hospitals,

Dr. Purita is a Fellow, American Academy of Orthopedic Surgeons; Fellow, American College of Surgeons; member, American Medical Association; member, Southern Medical Association; member, Palm Beach Medical Society; member, Broward County Medical Society; member, Palm Beach Orthopedic Society, and member, Florida Medical Association. His certifications include the American Board of Orthopedic Surgery; American College of Orthopaedic Surgery; American Board of Pain Management, and the American Board of Regenerative Medicine.

He is Is Board Certified By The Following Organizations:
•  American Board of Orthopedic Surgery
•  American College of Orthopaedic Surgery
•  American Board of Pain Management

Dr. Purita is a popular speaker at regenerative and orthopedic conferences worldwide.